My NCBISign In
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Rita Nahta, Francisco J Esteva
Breast Cancer Res. 2006; 8(6): 215. Published online 2006 November 6. doi: 10.1186/bcr1612
PMCID:
PMC1797036
Abstract Full Text PDF–75K

Is Cited by the Following 34 Articles in this Archive:

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
Punam Rana, Srikala S. Sridhar
Breast Cancer (Auckl) 2012; 6: 67–77. Published online 2012 March 7. doi: 10.4137/BCBCR.S6374
PMCID:
PMC3306225
Abstract Full Text PDF–571K
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
E Brain, N Isambert, F Dalenc, V Diéras, J Bonneterre, K Rezai, M Jimenez, F Mefti-Lacheraf, E Cottura, P Tresca, L Vanlemmens, C Mahier-Aït Oukhatar, F Lokiec, P Fumoleau
Br J Cancer. 2012 February 14; 106(4): 673–677. Published online 2012 January 12. doi: 10.1038/bjc.2011.591
PMCID:
PMC3322949
Free in PMC on 2013/02/14
Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
Cesar F. Ortega-Cava, Srikumar M. Raja, Zenab Laiq, Tameka A. Bailey, Haitao Luan, Bhopal Mohapatra, Stetson H. Williams, Aaron C. Ericsson, Rasna Goswami, Manjari Dimri, Lei Duan, Vimla Band, Mayumi Naramura, Hamid Band
J Carcinog. 2011; 10: 29. Published online 2011 November 30. doi: 10.4103/1477-3163.90443
PMCID:
PMC3243085
Abstract Full Text
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
Tameka A. Bailey, Haitao Luan, Robert J. Clubb, Mayumi Naramura, Vimla Band, Srikumar M. Raja, Hamid Band
J Carcinog. 2011; 10: 28. Published online 2011 November 30. doi: 10.4103/1477-3163.90442
PMCID:
PMC3243087
Abstract Full Text
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011
Christoph Thomssen, Anton Scharl, Nadia Harbeck
Breast Care (Basel) 2011 August; 6(4): 299–313. Published online 2011 August 30. doi: 10.1159/000331459
PMCID:
PMC3225216
Free in PMC on 2012/08/01
Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis
Jiemiao Hu, Xinli Liu, Dennis Hughes, Francisco J. Esteva, Bolin Liu, Joya Chandra, Shulin Li
PLoS One. 2011; 6(8): e23270. Published online 2011 August 10. doi: 10.1371/journal.pone.0023270
PMCID:
PMC3154407
Abstract Full Text PDF–887K
The emerging importance of α-L-fucose in human breast cancer: a review
Jay J Listinsky, Gene P Siegal, Catherine M Listinsky
Am J Transl Res. 2011 August 15; 3(4): 292–322. Published online 2011 July 20.
PMCID:
PMC3158734
Abstract Full Text PDF–719K
IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance
Colin D. White, Zhigang Li, Deborah A. Dillon, David B. Sacks
J Biol Chem. 2011 August 26; 286(34): 29734–29747. Published online 2011 July 1. doi: 10.1074/jbc.M111.220939
PMCID:
PMC3191015
Free in PMC on 2012/08/26
Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer
Naoki Hayashi, Takayuki Iwamoto, Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Ana Lluch, Naoki Niikura, Chandra Bartholomeusz, Seigo Nakamura, Gabriel N. Hortobagyi, Naoto T. Ueno
Oncologist. 2011 July; 16(7): 956–965. Published online 2011 June 28. doi: 10.1634/theoncologist.2010-0409
PMCID:
PMC3228141
Free in PMC on 2012/07/01
Combining Emerging Agents in Advanced Breast Cancer
Thehang Luu, Cathie Chung, George Somlo
Oncologist. 2011 June; 16(6): 760–771. Published online 2011 May 4. doi: 10.1634/theoncologist.2010-0345
PMCID:
PMC3228217
Free in PMC on 2012/06/01
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer
Ali Naderi, Kee Ming Chia, Ji Liu
Breast Cancer Res. 2011; 13(2): R36. Published online 2011 April 1. doi: 10.1186/bcr2858
PMCID:
PMC3219199
Abstract Full Text PDF–1.9M
Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer
E P Booy, E S Henson, S B Gibson
Oncogene. 2011 May 19; 30(20): 2367–2378. Published online 2011 January 24. doi: 10.1038/onc.2010.616
PMCID:
PMC3145838
Abstract Full Text PDF–801K Supplementary Material
Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers
Srikumar M Raja, Robert J Clubb, Cesar Ortega-Cava, Stetson H Williams, Tameka A Bailey, Lei Duan, Xiangshan Zhao, Alagarasamy L Reddi, Abijah M Nyong, Amarnath Natarajan, Vimla Band, Hamid Band
Cancer Biol Ther. 2011 January 15; 11(2): 263–276. Published online 2011 January 15. doi: 10.4161/cbt.11.2.13959
PMCID:
PMC3047084
Abstract Full Text PDF–12M Supplementary Material
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
Edgardo Rivera, Henry Gomez
Breast Cancer Res. 2010; 12(Suppl 2): S2. Published online 2010 October 22. doi: 10.1186/bcr2573
PMCID:
PMC2972556
Abstract Full Text PDF–407K
Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer
Zhiwei Hu, Jing Li
BMC Immunol. 2010; 11: 49. Published online 2010 October 12. doi: 10.1186/1471-2172-11-49
PMCID:
PMC2965132
Abstract Full Text PDF–1.2M
A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12
David J Klinke, II
Mol Cancer. 2010; 9: 242. Published online 2010 September 15. doi: 10.1186/1476-4598-9-242
PMCID:
PMC3243044
Abstract Full Text PDF–2.6M
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
David Cameron, Michelle Casey, Cristina Oliva, Beth Newstat, Bradley Imwalle, Charles E. Geyer
Oncologist. 2010 September; 15(9): 924–934. Published online 2010 August 24. doi: 10.1634/theoncologist.2009-0181
PMCID:
PMC3228041
Abstract Full Text PDF–630K
Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib
Charles Vogel, Arlene Chan, Brunilde Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim Moon
Jpn J Clin Oncol. 2010 November; 40(11): 999–1013. Published online 2010 June 11. doi: 10.1093/jjco/hyq084
PMCID:
PMC2964177
Abstract Full Text PDF–426K
Disruption Of Laminin-Integrin-CD151-FAK Axis Sensitizes Breast Cancer Cells To ErbB2 Antagonists
Xiuwei H. Yang, Ludmila M. Flores, Qinglin Li, Pengcheng Zhou, Fenghui Xu, Ian E. Krop, Martin E. Hemler
Cancer Res. Author manuscript; available in PMC 2012 March 22.
Published in final edited form as: Cancer Res. 2010 March 15; 70(6): 2256–2263. Published online 2010 March 2. doi: 10.1158/0008-5472.CAN-09-4032
PMCID:
PMC3310185
Abstract Full Text PDF–1.4M Supplementary Material
Mechanism of Lapatinib-Mediated Radiosensitization of Breast Cancer Cells is Primarily by Inhibition of the Raf>MEK>ERK Mitogen-Activated Protein Kinase Cascade and Radiosensitization of Lapatinib-Resistant Cells Restored by Direct Inhibition of MEK
Maria J. Sambade, J. Terese Camp, Randall J. Kimple, Carolyn I. Sartor, Janiel M. Shields
Radiother Oncol. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as: Radiother Oncol. 2009 December; 93(3): 639–644. Published online 2009 October 23. doi: 10.1016/j.radonc.2009.09.006
PMCID:
PMC2799330
Abstract Full Text PDF–629K Supplementary Material
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
M Toi, H Iwata, Y Fujiwara, Y Ito, S Nakamura, Y Tokuda, T Taguchi, Y Rai, K Aogi, T Arai, J Watanabe, T Wakamatsu, K Katsura, C E Ellis, R C Gagnon, K E Allen, Y Sasaki, S Takashima
Br J Cancer. 2009 November 17; 101(10): 1676–1682. Published online 2009 October 20. doi: 10.1038/sj.bjc.6605343
PMCID:
PMC2778543
Abstract Full Text PDF–386K
Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
Andrea Sassen, Simone Diermeier-Daucher, Manuela Sieben, Olaf Ortmann, Ferdinand Hofstaedter, Stephan Schwarz, Gero Brockhoff
Breast Cancer Res. 2009; 11(4): R50. Published online 2009 July 22. doi: 10.1186/bcr2339
PMCID:
PMC2750111
Abstract Full Text PDF–406K
Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Javier A. Menendez
PLoS One. 2009; 4(7): e6251. Published online 2009 July 16. doi: 10.1371/journal.pone.0006251
PMCID:
PMC2708925
Abstract Full Text PDF–1.2M Supplementary Material
HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu Modi
Biologics. 2009; 3: 289–301. Published online 2009 July 13.
PMCID:
PMC2726059
Abstract Full Text PDF–270K
Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer
Hannah Jörißen, Nuran Bektas, Edgar Dahl, Arndt Hartmann, Anette ten Haaf, Stefano Di Fiore, Hans Kiefer, Andreas Thess, Stefan Barth, Torsten Klockenbring
BMC Cancer. 2009; 9: 200. Published online 2009 June 24. doi: 10.1186/1471-2407-9-200
PMCID:
PMC2711971
Abstract Full Text PDF–2.1M Supplementary Material
IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons
S. John Weroha, Paul Haluska
J Mammary Gland Biol Neoplasia. Author manuscript; available in PMC 2009 August 18.
Published in final edited form as: J Mammary Gland Biol Neoplasia. 2008 December; 13(4): 471–483. Published online 2008 November 21. doi: 10.1007/s10911-008-9104-6
PMCID:
PMC2728362
Abstract Full Text PDF–557K
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathwaydependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
Srikumar M. Raja, Robert J. Clubb, Mitra Bhattacharyya, Manjari Dimri, Hao Cheng, Wei Pan, Cesar Ortega-Cava, Alagarsamy Lakku-Reddi, Mayumi Naramura, Vimla Band, Hamid Band
Cancer Biol Ther. Author manuscript; available in PMC 2009 October 1.
Published in final edited form as: Cancer Biol Ther. 2008 October; 7(10): 1630–1640. Published online 2008 October 9.
PMCID:
PMC2727620
Abstract Full Text PDF–1.7M Supplementary Material
Breast Cancer Survival among Economically Disadvantaged Women: The Influences of Delayed Diagnosis and Treatment on Mortality
Emily Rose Smith, Swann Arp Adams, Irene Prabhu Das, Matteo Bottai, Jeanette Fulton, James R. Hebert
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2010 October 22.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2008 October; 17(10): 2882–2890. Published online 2008 October 3. doi: 10.1158/1055-9965.EPI-08-0221
PMCID:
PMC2959167
Abstract Full Text PDF–80K
A sequence-based survey of the complex structural organization of tumor genomes
Benjamin J Raphael, Stanislav Volik, Peng Yu, Chunxiao Wu, Guiqing Huang, Elena V Linardopoulou, Barbara J Trask, Frederic Waldman, Joseph Costello, Kenneth J Pienta, Gordon B Mills, Krystyna Bajsarowicz, Yasuko Kobayashi, Shivaranjani Sridharan, Pamela L Paris, Quanzhou Tao, Sarah J Aerni, Raymond P Brown, Ali Bashir, Joe W Gray, Jan-Fang Cheng, Pieter de Jong, Mikhail Nefedov, Thomas Ried, Hesed M Padilla-Nash, Colin C Collins
Genome Biol. 2008; 9(3): R59. Published online 2008 March 25. doi: 10.1186/gb-2008-9-3-r59
PMCID:
PMC2397511
Abstract Full Text PDF–1.3M Supplementary Material
Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer
Nuran Bektas, Anette ten Haaf, Jürgen Veeck, Peter Johannes Wild, Juliane Lüscher-Firzlaff, Arndt Hartmann, Ruth Knüchel, Edgar Dahl
BMC Cancer. 2008; 8: 42. Published online 2008 February 6. doi: 10.1186/1471-2407-8-42
PMCID:
PMC2265720
Abstract Full Text PDF–584K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk